[
    {
        "@id": "http://purl.org/np/RAXg36EOYecQ6V3sA5LY5dRzN7GSlpknhS3bEtas3rIMA#assertion",
        "@graph": [
            {
                "@id": "http://purl.obolibrary.org/obo/DOID_4362",
                "https://w3id.org/biolink/vocab/category": [
                    {
                        "@id": "https://w3id.org/biolink/vocab/Disease"
                    }
                ]
            },
            {
                "@id": "http://purl.org/np/RAXg36EOYecQ6V3sA5LY5dRzN7GSlpknhS3bEtas3rIMA#association",
                "http://www.w3.org/1999/02/22-rdf-syntax-ns#object": [
                    {
                        "@id": "http://purl.obolibrary.org/obo/DOID_4362"
                    }
                ],
                "http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate": [
                    {
                        "@id": "https://w3id.org/biolink/vocab/treats"
                    }
                ],
                "http://www.w3.org/1999/02/22-rdf-syntax-ns#subject": [
                    {
                        "@id": "https://identifiers.org/drugbank:DB01030"
                    }
                ],
                "@type": [
                    "http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement"
                ],
                "http://www.w3.org/2000/01/rdf-schema#label": [
                    {
                        "@value": "topotecan hydrochloride for injection is a topoisomerase inhibitor indicated for treatment of patients with metastatic ovarian cancer after disease progression on or after initial or subsequent chemotherapy as a single agent 1 1 patients with small cell lung cancer slsc platinum sensitive disease who progressed at least 6 days after initiation of first line chemotherapy as a single agent 1 2 patients with stage iv b recurrent or persistent cervical cancer which is not amenable to curative treatment in combination with cisplatin 1 3 topotecan hydrochloride for injection as a single agent is indicated for the treatment of patients with metastatic ovarian cancer after disease progression on or after initial or subsequent chemotherapy topotecan hydrochloride for injection as a single agent is indicated for the treatment of patients with small cell lung cancer sclc with platinum sensitive disease who progressed at least 6 days after initiation of first line chemotherapy topotecan hydrochloride for injection in combination with cisplatin is indicated for the treatment of patients with stage iv b recurrent or persistent cervical cancer of the cervix not amenable to curative treatment"
                    }
                ],
                "https://w3id.org/biolink/vocab/association_type": [
                    {
                        "@id": "https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation"
                    }
                ],
                "https://w3id.org/biolink/vocab/provided_by": [
                    {
                        "@id": "https://w3id.org/um/NeuroDKG"
                    }
                ],
                "https://w3id.org/biolink/vocab/relation": [
                    {
                        "@id": "https://w3id.org/um/neurodkg/SymptomaticReliefIndication"
                    }
                ]
            },
            {
                "@id": "https://identifiers.org/drugbank:DB01030",
                "https://w3id.org/biolink/vocab/category": [
                    {
                        "@id": "https://w3id.org/biolink/vocab/Drug"
                    }
                ]
            }
        ]
    },
    {
        "@id": "http://purl.org/np/RAXg36EOYecQ6V3sA5LY5dRzN7GSlpknhS3bEtas3rIMA#provenance",
        "@graph": [
            {
                "@id": "http://purl.org/np/RAXg36EOYecQ6V3sA5LY5dRzN7GSlpknhS3bEtas3rIMA#assertion",
                "http://www.w3.org/ns/prov#wasAttributedTo": [
                    {
                        "@id": "https://orcid.org/0000-0002-1468-3557"
                    }
                ]
            }
        ]
    },
    {
        "@id": "http://purl.org/np/RAXg36EOYecQ6V3sA5LY5dRzN7GSlpknhS3bEtas3rIMA#Head",
        "@graph": [
            {
                "@id": "http://purl.org/np/RAXg36EOYecQ6V3sA5LY5dRzN7GSlpknhS3bEtas3rIMA",
                "http://www.nanopub.org/nschema#hasAssertion": [
                    {
                        "@id": "http://purl.org/np/RAXg36EOYecQ6V3sA5LY5dRzN7GSlpknhS3bEtas3rIMA#assertion"
                    }
                ],
                "http://www.nanopub.org/nschema#hasProvenance": [
                    {
                        "@id": "http://purl.org/np/RAXg36EOYecQ6V3sA5LY5dRzN7GSlpknhS3bEtas3rIMA#provenance"
                    }
                ],
                "http://www.nanopub.org/nschema#hasPublicationInfo": [
                    {
                        "@id": "http://purl.org/np/RAXg36EOYecQ6V3sA5LY5dRzN7GSlpknhS3bEtas3rIMA#pubinfo"
                    }
                ],
                "@type": [
                    "http://www.nanopub.org/nschema#Nanopublication"
                ]
            }
        ]
    },
    {
        "@id": "http://purl.org/np/RAXg36EOYecQ6V3sA5LY5dRzN7GSlpknhS3bEtas3rIMA#pubinfo",
        "@graph": [
            {
                "@id": "http://purl.org/np/RAXg36EOYecQ6V3sA5LY5dRzN7GSlpknhS3bEtas3rIMA#sig",
                "http://purl.org/nanopub/x/hasAlgorithm": [
                    {
                        "@value": "RSA"
                    }
                ],
                "http://purl.org/nanopub/x/hasPublicKey": [
                    {
                        "@value": "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB"
                    }
                ],
                "http://purl.org/nanopub/x/hasSignature": [
                    {
                        "@value": "A1bcyH9iLCy/J+XwgmdOvp5oWB51g6GzeamPPJapNkZVWc1D2lkwXmrmihK+/31QVu5XzKOTvMsMihlMdGKonQ3MPtn4b4ZAaao9GeS+4LVae6Iavlzs9rLTeFWvZC21cSEox1Dud4JGKPGJK/wfJfw7LgiSrmjRjqTWoGFw6GY="
                    }
                ],
                "http://purl.org/nanopub/x/hasSignatureTarget": [
                    {
                        "@id": "http://purl.org/np/RAXg36EOYecQ6V3sA5LY5dRzN7GSlpknhS3bEtas3rIMA"
                    }
                ]
            },
            {
                "@id": "http://purl.org/np/RAXg36EOYecQ6V3sA5LY5dRzN7GSlpknhS3bEtas3rIMA",
                "http://purl.org/dc/terms/created": [
                    {
                        "@value": "2021-07-03T14:12:13.725+02:00",
                        "@type": "http://www.w3.org/2001/XMLSchema#dateTime"
                    }
                ],
                "http://purl.org/dc/terms/creator": [
                    {
                        "@id": "https://orcid.org/0000-0002-1468-3557"
                    }
                ],
                "https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate": [
                    {
                        "@id": "http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM"
                    }
                ],
                "https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate": [
                    {
                        "@id": "http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM"
                    }
                ],
                "https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate": [
                    {
                        "@id": "http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs"
                    }
                ]
            }
        ]
    }
]